Patent ductus arteriosus treated with ligation or indomethacin: a follow-up study.
The course and complications of fifty-two infants with patent ductus arteriosus requiring closure were assessed prospectively. Twenty-six infants with a PDA received indomethacin for pharmacologic closure of the PDA, and 26 underwent ligation. The current study analyzes and compares the longitudinal follow-up with respect to somatic growth, neurologic function, psychomotor and mental development, and renal, ophthalmologic, and audiologic function in 21 infants in each group who entered the follow-up. No selective morbidity was attributable to PDA closure with indomethacin when compared to surgically treated infants.
D002657:Child Development; D004374:Ductus Arteriosus, Patent / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D005500:Follow-Up Studies; D006128:Growth / Q000187:drug effects; D006304:Health Status; D006801:Humans; D007213:Indomethacin / Q000009:adverse effects / Q000627:therapeutic use*; D007223:Infant; D007231:Infant, Newborn; D008026:Ligation; D009460:Neurologic Examination; D010349:Patient Compliance; D011183:Postoperative Complications; D011446:Prospective Studies; D014786:Vision Disorders / Q000209:etiology
D007213:Indomethacin